These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 28122330)

  • 21. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
    Wu P; Zheng Y; Wang Y; Wang Y; Liang N
    J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of an endoplasmic reticulum stress-associated lncRNA prognostic signature and the tumor-suppressive role of RP11-295G20.2 knockdown in lung adenocarcinoma.
    Yu L; Zhou S; Hong W; Lin N; Wang Q; Liang P
    Sci Rep; 2024 May; 14(1):12283. PubMed ID: 38811828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methylation and transcriptome analysis reveal lung adenocarcinoma-specific diagnostic biomarkers.
    Li R; Yang YE; Yin YH; Zhang MY; Li H; Qu YQ
    J Transl Med; 2019 Sep; 17(1):324. PubMed ID: 31558162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of m6A/m5C/m1A regulated lncRNA signature for prognostic prediction, personalized immune intervention and drug selection in LUAD.
    Ma C; Gu Z; Yang Y
    J Cell Mol Med; 2024 Apr; 28(8):e18282. PubMed ID: 38647237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A potential prognostic lncRNA signature for predicting survival in patients with bladder urothelial carcinoma.
    Bao Z; Zhang W; Dong D
    Oncotarget; 2017 Feb; 8(6):10485-10497. PubMed ID: 28060759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Seven-Long Non-coding RNA Signature Improves Prognosis Prediction of Lung Adenocarcinoma: An Integrated Competing Endogenous RNA Network Analysis.
    Li R; Han K; Xu D; Chen X; Lan S; Liao Y; Sun S; Rao S
    Front Genet; 2020; 11():625977. PubMed ID: 33584817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A three-lncRNA signature predicts overall survival and disease-free survival in patients with esophageal squamous cell carcinoma.
    Huang GW; Xue YJ; Wu ZY; Xu XE; Wu JY; Cao HH; Zhu Y; He JZ; Li CQ; Li EM; Xu LY
    BMC Cancer; 2018 Feb; 18(1):147. PubMed ID: 29409459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
    Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
    Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A seven-long noncoding RNA signature predicts overall survival for patients with early stage non-small cell lung cancer.
    Lin T; Fu Y; Zhang X; Gu J; Ma X; Miao R; Xiang X; Niu W; Qu K; Liu C; Wu Q
    Aging (Albany NY); 2018 Sep; 10(9):2356-2366. PubMed ID: 30205363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of a multidimensional transcriptome prognostic signature for lung adenocarcinoma.
    Ye J; Liu H; Xu ZL; Zheng L; Liu RY
    J Clin Lab Anal; 2019 Nov; 33(9):e22990. PubMed ID: 31402485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and Validation of Lactate Metabolism-Related lncRNA Signature as a Prognostic Model for Lung Adenocarcinoma.
    Mai S; Liang L; Mai G; Liu X; Diao D; Cai R; Liu L
    Front Endocrinol (Lausanne); 2022; 13():829175. PubMed ID: 35422758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel autophagy-related lncRNA survival model for lung adenocarcinoma.
    Wu L; Wen Z; Song Y; Wang L
    J Cell Mol Med; 2021 Jun; 25(12):5681-5690. PubMed ID: 33987935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overexpression of LncRNA-UCA1 Correlates with Lung Adenocarcinoma Progression and Poor Prognosis.
    Chen L; Cao P; Wu Q; Guo Y; Yang Y; Chen F
    Clin Lab; 2019 Mar; 65(3):. PubMed ID: 30868851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential Prognostic Biomarkers of Lung Adenocarcinoma Based on Bioinformatic Analysis.
    Hou J; Yao C
    Biomed Res Int; 2021; 2021():8859996. PubMed ID: 33511215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive analysis of lncRNA expression profiles and identification of functional lncRNAs in lung adenocarcinoma.
    Qiu M; Feng D; Zhang H; Xia W; Xu Y; Wang J; Dong G; Zhang Y; Yin R; Xu L
    Oncotarget; 2016 Mar; 7(13):16012-22. PubMed ID: 26918601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Construction of an immune-related lncRNA signature as a novel prognosis biomarker for LUAD.
    Chen H; Shen W; Ni S; Sang M; Wu S; Mu Y; Liu K; Li N; Zhu L; Xu G
    Aging (Albany NY); 2021 Aug; 13(16):20684-20697. PubMed ID: 34438369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A nine-long non-coding RNA signature for prognosis prediction of patients with lung squamous cell carcinoma.
    Huang G; Huang Q; Xie Z; Zhou H; Cao J; Shi L; Yang M
    Cancer Biomark; 2019; 26(3):239-247. PubMed ID: 31524143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival.
    Huang TB; Dong CP; Zhou GC; Lu SM; Luan Y; Gu X; Liu L; Ding XF
    Int Urol Nephrol; 2017 May; 49(5):825-835. PubMed ID: 28188414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of a New Eight-Long Noncoding RNA Molecular Signature for Breast Cancer Survival Prediction.
    Zhang Y; Li Z; Chen M; Chen H; Zhong Q; Liang L; Li B
    DNA Cell Biol; 2019 Dec; 38(12):1529-1539. PubMed ID: 31647329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LncRNAs are altered in lung squamous cell carcinoma and lung adenocarcinoma.
    Liu B; Chen Y; Yang J
    Oncotarget; 2017 Apr; 8(15):24275-24291. PubMed ID: 27903974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.